This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Flagship VentureLabs™ Launches Pronutria To Prevent And Treat Diseases With Novel Protein Nutrients

CAMBRIDGE, Mass., Oct. 22, 2013 /PRNewswire/ -- Flagship VentureLabs announces the launch of Pronutria after two years of development in stealth mode and $10.8 million in Series A investments during that period from Flagship Ventures.  The company is currently advancing into human clinical testing its lead ProNutrein™ programs to improve health and treat significant medical conditions mediated by amino acid biology, including muscle, metabolic, and rare diseases.  Pronutria has created a revolutionary platform for identifying proteins in the human diet that, when delivered in pure form, provide a preferred balance of amino acids that elicit a pharmacological effect, important in the setting of a wide range of diseases.  ProNutrein™ products offer a vast untapped source of safe, breakthrough medicines.

ProNutrein™ products are naturally occurring, orally consumed pure protein products that trigger pharmacological effects through precise and reproducible delivery of specific amino acids. The ProNutrein™ product platform leverages a wealth of advanced biotechnology tools, typically applied to drug discovery, that Pronutria has applied to the human diet for the first time, allowing for the identification and development of a large family of pharmaconutrients - nutrients identified in food that can be developed initially as medical foods or dietary supplements and eventually as drugs. The company's discovery strategy builds upon decades of amino acid clinical trial data that validate the potent health benefits of pure and precise amino acid delivery for many indications.  By tapping into the enormous power of amino acid pharmacology, and with the large library of protein nutrients that can deliver it, Pronutria plans to build pharmaconutrients into a major class of new products. 

Amino acid mediated biology is at the heart of a wide range of medical conditions, and both drugs and medical foods that affect this biology can play a critical role in their treatment and support.  Patients with rare diseases, such phenylketonuria, have an inability to properly metabolize specific amino acids.  Other diseases, such as inflammatory bowel disease and cystic fibrosis, suffer from impaired amino acid uptake which exacerbates disease.  And millions suffer from muscle and metabolic diseases where there is a mechanistic link between amino acid biology and the underlying disease pathophysiology.  The ProNutrein™ product platform allows for the tailored selection of proteins ideal for each of these indications that could play a significant role in disease prevention and treatment.

1 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free


Chart of I:DJI
DOW 17,812.19 +19.51 0.11%
S&P 500 2,089.14 +2.55 0.12%
NASDAQ 5,102.8080 +0.33 0.01%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs